[CLSTR]
< Back to situation

[REVISION HISTORY]

Kratom and 7-OH health and regulatory concerns

Updated 2 times since CLSTR started tracking revisions of this situation.

What changed

2026-10-09 09:43 UTC → 2026-10-13 03:40 UTC · added removed

Health officials and addiction specialists have raised concerns regarding the rising use of concentrated 7-hydroxymitragynine (7-OH), a compound found in the kratom plant. While kratom is derived from the Mitragyna speciosa tree, new products such as tablets, gummies, and extracts contain much higher concentrations of 7-OH than what is found in nature. The FDA has warned that these concentrated products can produce potent opioid-like effects, potentially leading to dependence and withdrawal. Medical professionals have reported an increase in pregnant patients using kratom, resulting in cases of neonatal abstinence syndrome where newborns experience withdrawal symptoms after birth. syndrome. Dr. Angad Madan, medical director of St. Peter’s Addiction Recovery Center, has described kratom as a potent opioid agonist that can be “at least 13 times more potent than morphine.” In response to these health risks, legislative pressure is growing in New York. A ban on the concentrated form of 7-OH has passed both the New York State Assembly and Senate, awaiting the Governor's signature. Furthermore, Albany County has declared kratom a danger to life and health through an emergency public health order following reports of fatalities. At the federal level, authorities the U.S. Department of Justice and the DEA have placed three laboratory-modified opioids derived from kratom—MGPI, MGM-15, and MGM-16—into Schedule I of the Controlled Substances Act. The U.S. Department of Justice and the DEA identified these compounds as posing significant Act due to risks of addiction and respiratory depression. However, researchers at Rutgers Health warned that such restrictions could hinder medical studies into treatments for pain and opioid dependence. Experts continue In a recent development, the U.S. Department of Justice announced revisions to emphasize its emergency scheduling guidelines following updated scientific findings from the distinction Department of Health and Human Services (HHS). The DEA plans to issue two new Notices of Intent regarding substances including 7-OH and MGPI. Under proposed HHS recommendations, Schedule I controls would apply if 7-OH or MGPI exceeds specific concentration thresholds in solid or liquid products, or if the ratio of mitragynine to these substances falls below 100 to 1. This approach seeks to distinguish between traditional naturally occurring botanical kratom compounds and highly concentrated or chemically modified manufactured high-concentration products.

Versions

  1. 2026-10-13 03:40 UTC Kratom and 7-OH health and regulatory concerns
  2. 2026-10-09 09:43 UTC Kratom and 7-OH health and regulatory concerns
  3. 2026-09-24 00:18 UTC Kratom and 7-OH health and regulatory concerns

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.